摘要
目的观察不同剂量瑞舒伐他汀对急性冠状动脉综合征(acute coronary syndrome,ACS)患者血清C-反应蛋白(C-reactive protein,CRP)、尿酸(uric acid,UA)及血脂水平的影响。方法选择ACS 48例随机分为A、B组,每组24例,在扩张冠状动脉、改善周围循环的基础上,A组予瑞舒伐他汀5 mg/d口服,B组予瑞舒伐他汀10 mg/d口服。治疗8周后采集患者静脉血检测CRP、UA、血脂,并观察两组治疗过程中的不良反应。结果两组治疗后与本组治疗前比较,CRP、UA、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)显著降低,高密度脂蛋白胆固醇(HDL-C)显著升高(P<0.05);两组治疗前CRP、UA、血脂水平差异无统计学意义(P>0.05),治疗后CRP、UA、TC、LDL-C比较差异无统计学意义(P>0.05),B组TG低于A组(P<0.05),HDL-C高于A组(P<0.05)。两组均未出现严重不良反应。结论瑞舒伐他汀能有效改善ACS患者血清CRP、UA和血脂水平,治疗剂量为10 mg/d时效果更佳。
Objective To observe the influence of different doses of Rosuvastatin on levels of serum C-reactive protein （CRP）, uric acid （UA） and blood lipid of patients with acute coronary syndrome （ACS）. Methods A total of 48 patients with ACS were randomly divided into group A and B （ n = 24）. Based on expanding coronary arteries and im- proving the peripheral circulation, group A was treated with 5 mg/d Rosuvastatin orally, and group B was treated with 10 mg/d Rosuvastatin orally. After treatment for 8 weeks in the two groups, levels of CRP, UA and blood lipid were de- tected by extracting the venous blood, and adverse reactions were observed. Results Compared with those before treat- ment in the same group, levels of CRP, UA, total cholesterol （TC） , triglyceride （TG） and low density lipoprotein cho- lesterol （LDL-C） were significantly lower, and high density lipoprotein cholesferol （HDL-C） level was significantly high- er after treatment （P 〈0.05）; there were no significantly differences in levels of CRP, UA and blood lipid in the two groups before treatment （P 〉 0.05） ; there were no significantly differences in levels of CRP, UA, TC and LDL-C in the two groups after treatment （P 〉 0.05 ）, the TG level in group B was significantly lower than that in group A （P 〈 0. 05）, while the HDL-C level in group B was significantly higher than that in group A （P 〈 0. 05）. There was no severe adverse reaction in the two groups. Conclusion Rosuvastatin can effectively improve the levels of serum CRP, UA and blood lipid, and 10 mg/d Rosuvastatin may achieve better effect.
出处
《解放军医药杂志》
CAS
2014年第2期75-77,共3页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
辽宁省科学计划发展项目(20092250511)
